...
首页> 外文期刊>The Indian journal of tuberculosis >A SURVEY OF PRESCRIBING PATTERN FOR OSTEOARTICULAR TUBERCULOSIS: ORTHOPAEDIC SURGEONS' AND INFECTIOUS DISEASE EXPERTS' PERSPECTIVE
【24h】

A SURVEY OF PRESCRIBING PATTERN FOR OSTEOARTICULAR TUBERCULOSIS: ORTHOPAEDIC SURGEONS' AND INFECTIOUS DISEASE EXPERTS' PERSPECTIVE

机译:骨关节炎的处方模式调查:矫形外科医师和感染性疾病专家的观点

获取原文
获取原文并翻译 | 示例

摘要

Introduction: This study examines the perspective of senior orthopaedic faculty and infectious disease experts from the Indian subcontinent and other countries on the appropriate duration of multi drug antitubercular chemotherapy in osteoarticular tuberculosis. Material and methods: A questionnaire regarding what antitubercular drugs, their dosage and for how long was asked to attending faculty in an International Conference on musculoskeletal infections. Results: Thirty different prescriptions were obtained from a total of 52 respondents. Forty-two respondents voted against short course (6 months) regimen. The mode value for duration of treatment with isoniazid and rifampicin treatment in the study was 12 months; for pyrazinamide, it was three months. There was almost no consensus over the duration of treatment with ethambutol. Conclusion: There is a strong need to assess long term impact of DOTS in osteoarticular tuberculosis to facilitate the National Tuberculosis Programme planning, uniform training, wider acceptance, drug ordering and distribution. An effective communication between those planning national tuberculosis programmes and experts in osteoarticular tuberculosis is essential for universal acceptance of the management protocols.
机译:简介:本研究探讨了印度次大陆和其他国家的高级骨科教授和传染病专家对于骨关节炎的多药抗结核化疗的适当持续时间的观点。资料和方法:一份关于抗结核药物,其剂量以及在国际骨骼肌肉感染大会上要求参加教师多长时间的问卷。结果:总共52位受访者获得了30种不同的处方。 42名受访者投票反对短期课程(6个月)方案。该研究中异烟肼和利福平治疗持续时间的众数值为12个月;吡嗪酰胺需要三个月。乙胺丁醇治疗期间几乎没有共识。结论:迫切需要评估DOTS对骨关节结核的长期影响,以促进国家结核病计划的规划,统一培训,更广泛的接受,药物订购和分配。那些正在计划国家结核病规划的人员与骨关节结核专家之间的有效沟通对于普遍接受管理规程至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号